• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19

tetano

Editor, Senior Moderator
J Infect Chemother


. 2020 Aug 20;S1341-321X(20)30294-4.
doi: 10.1016/j.jiac.2020.08.014. Online ahead of print.
Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19


Ippei Sakamaki[SUP] 1 [/SUP], Yoshitomo Morinaga[SUP] 2 [/SUP], Hideki Tani[SUP] 2 [/SUP], Yusuke Takegoshi[SUP] 3 [/SUP], Yasutaka Fukui[SUP] 3 [/SUP], Hitoshi Kawasuji[SUP] 3 [/SUP], Akitoshi Ueno[SUP] 3 [/SUP], Yuki Miyajima[SUP] 3 [/SUP], Masahiro Wakasugi[SUP] 4 [/SUP], Toshiomi Kawagishi[SUP] 4 [/SUP], Hroyuki Kuwano[SUP] 4 [/SUP], Tomoya Hatano[SUP] 4 [/SUP], Tadaki Shibuya[SUP] 4 [/SUP], Hiroshi Okudera[SUP] 4 [/SUP], Yoshihiro Yamamoto[SUP] 3 [/SUP]



Affiliations

Abstract

Most patients with coronavirus disease 2019 (COVID-19) have just only mild symptoms, but about 5% are very severe. Although extracorporeal membranous oxygenation (ECMO) is sometimes used in critically patients with COVID-19, ECMO is only an adjunct, not the main treatment. If the patient's condition deteriorates and it is determined to be irreversible, it is necessary to decide to stop ECMO. A 54-year-old man was admitted on day 6 of onset with a chief complaint of high fever and cough. Computed tomography (CT) showed a ground glass opacity in both lungs, and reverse transcription-polymerase chain reaction (RT-PCR) diagnosed COVID-19. He was admitted to the hospital and started to receive oxygen and favipiravir. After that, his respiratory condition deteriorated, and he was intubated and ventilated on day 9 of onset, and ECMO was introduced on day 12. Two days after the introduction of ECMO, C-reactive protein (CRP) increased, chest X-p showed no improvement in pneumonia, and PaO2/FiO2 decreased again. As D-dimer rose and found a blood clot in the ECMO circuit, we had to decide whether to replace the circuit and continue with ECMO or stop ECMO. At this time, the viral load by RT-PCR was drastically reduced to about 1/1750. We decided to continue ECMO therapy and replaced the circuit. The patient's respiratory status subsequently improved and ECMO was stopped on day 21 of onset. In conclusion, viral load measurement by RT-PCR may be one of the indicators for promoting the treatment of severe COVID-19 patients.

Keywords: Coronavirus disease 2019 (COVID-19); Extracorporeal membranous oxygenation (ECMO); Reverse transcription-polymerase chain reaction (RT-PCR); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
 
Back
Top Bottom